Zentalis Pharmaceuticals Investor Presentation — September 2020

Document content

Creating Differentiated Therapies to Improve

the Lives of Cancer PatientsForward -Looking Statements and Disclaimer

2Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “ Zentalis ” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains f orward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this prese ntation that do not relate to matters of historical fact should be considered

forward -looking statements, including without limitation statements regarding our future financial or business performance, plan s, prospects, trends or strategies, objectives of management,

competition and other financial and business matters; the potential, safety, efficacy, and regulatory and clinical progress o f our current and prospective product candidates, planned clinical trials and

preclinical activities, and projected research and development costs; our current and prospective collaborations; the estimat ed size of the market for our product candidates; and the timing and success

of our development and commercialization of our anticipated product candidates and the market acceptance thereof are forward -looking statements, as well as statements that include the words

“expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statement s of a future or forward -looking nature. These statements are neither

promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our ac tual results, performance or achievements to be materially different

from any future results, performance or achievements expressed or implied by the forward -looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus

disease, COVID -19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies a nd clinical trials; our limited operating history, which may make it

difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to in cursignificant losses; our need for additional funding, which may not be

available; our substantial dependence on the success of our lead product candidate; failure to identify additional product ca ndidates and develop or commercialize marketable products; the early stage

of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequenc es;risks relating to the regulatory approval process or ongoing regulatory

obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse sid e effects; inability to maintain our collaborations, or the failure of these